SWOG clinical trial number
CTSU/E1910

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults

Closed
Phase
Abbreviated Title
PIII Rando Blinatumomab for New BCR-ABL-Neg B-ALL
Activated
01/15/2014
Participants
CTSU

Research committees

Leukemia

Treatment

Cyclophosphamide Dexamethasone Vincristine 6-Mercaptopurine Daunomycin Etoposide Leucovorin Calcium Methotrexate PEG-L-Asparaginase Cytarabine Blinatumomab Erwinase

Eligibility Criteria Expand/Collapse

SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2024

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

N Podoltsev;Z Sun;M Litzow;E Paietta;K Roberts;Y Xhang;J Racevckis;H Lazarus;J Rowe;D Arber;M Wieduwilt;M Liedtke;J Bergeron;B Wood;Y Zhao;G Wu;T Chang;W Zhang;K Pratz;S Dinner;N Frey;S Gore;B Bhatnagar;E Atallah;G Uy;D Jeyakumar;T Lin;C Willman;D De Angelo;S Patel;M Elliott;A Advani;D Tzachanis;P Vachhani;R Bhave;E Sharon;R Little;H Erba;R Stone;C Mullighan;M Tallman;S Luger;R Mattison ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster

Assessment of Outcomes of Allogeneic Stem Cell Transplantation by Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial

M Liedtke;Z Sun;M Litzow;R Mattison;E Paietta;K Roberts;Y Zhang;J Racevckis;H Lazarus;J Rowe;D Arber;J Bergeron;B Wood;Y Zhao;G Wu;T Chang;W Zhang;K Pratz;S Dinner;N Frey;S Gore;B Bhatnagar;E Atallah;G Uy;D Jeyakumar;T Lin;C Willman;D DeAngelo;S Patel;M Elliott;A Advani;D Tzachanis;P Vachhani;R Bhave;E Sharon;R Little;H Erba;R Stone;C Mullighan;M Tallman;S Luger;M Wieduwilt ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral

2023

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

S Luger;X Sun;R Mattison;E Paietta;K Roberts;Y Zhang;J Racevckis;H Lazarus;J Rowe;D Arber;M Wieduwilt;M Liedtke;J Bergeron;B Wood;Y Zhao;G Wu;T Chang;W Zhang;K Pratz;S Dinner;N Frey;S Gore;B Bhatnagar;E Atallah;G Uy;D Jeyakumar;T Lin;C Willman;D DeAngelo;E Sharon;R Little;H Erba;R Stone;C Mullighan;M Litzow;M Tallman ASH Annual Meeting (Dec9-12,2023, San Diego, CA), poster

Other Clinical Trials

SWOG Clinical Trial Number
S2507

A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2A Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) with Persistent Measurable Residual Disease (MRD)
Research Committee(s)
Leukemia
Other
Activated
09/22/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2504

A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)
Research Committee(s)
Leukemia
Lymphoma
Activated
06/01/2026
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/A042302

Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Research Committee(s)
Leukemia
Activated
03/06/2026
Open
Phase